论文部分内容阅读
目的 Basedonitshighefficacyandgoodtolerance,alectinib,asecondgenerationselectiveanaplasticlymphomakinase(ALK)inhibitor,mayplayacentralroleinthetreatmentofALK-positivelungcancerpatientsinthenearfuture.However,acquiredresistanceremainsalimitationofitsefficacy.Hepatocytegrowthfactor(HGF)andMETreceptorexpressionsignificantlyincreasedinALK-positivenonsmallcelllungcancer(NSCLC),andisassociatedwithresistancetoalectinib.